Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
1.730
-0.020 (-1.14%)
Dec 5, 2025, 4:00 PM EST - Market closed
Protalix BioTherapeutics Employees
Protalix BioTherapeutics had 213 employees as of December 31, 2024. The number of employees increased by 5 or 2.40% compared to the previous year.
Employees
213
Change (1Y)
5
Growth (1Y)
2.40%
Revenue / Employee
$290,329
Profits / Employee
$25,324
Market Cap
139.13M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PLX News
- 23 days ago - Protalix BioTherapeutics, Inc. (PLX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results - PRNewsWire
- 4 weeks ago - Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025 - PRNewsWire
- 4 weeks ago - PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewsWire
- 4 weeks ago - Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU - GlobeNewsWire
- 7 weeks ago - Why Is Protalix BioTherapeutics Stock Falling On Friday? - Benzinga
- 7 weeks ago - Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU - GlobeNewsWire
- 3 months ago - Protalix BioTherapeutics to Present at Investor Summit Virtual - Accesswire